Your session is about to expire
← Back to Search
NovoTTF-200A for Glioblastoma
Study Summary
This trial is designed to study the safety and feasibility of using a medical device, NovoTTF-200A, with standard adjuvant treatment for newly diagnosed glioblastoma.
- Glioblastoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What maladies has NovoTTF-200A been established to alleviate?
"The NovoTTF-200A device is commonly employed to address issues related to nitrosourea therapy. Additionally, it has proven effective at treating certain advanced cases of mycosis fungoides, refractory neuroblastoma, and directives which are resistant to other treatments."
Is this project presently enrolling new participants?
"This trial has stopped recruitment, having been initially posted on July 26th 2017 and last updated October 7th 2022. Currently, 442 studies are sourcing patients with glioblastoma while 206 trials seek volunteers for NovoTTF-200A treatment."
Is this the inaugural investigation of its kind?
"Since its inception in 2002, NovoTTF-200A has been subject to numerous clinical trials. The initial trial was conducted by Schering-Plough and included 60 participants; following this study, the drug gained Phase 2 approval from regulatory bodies. Nowadays, there are 206 active investigations involving this medication scattered across 36 countries and 935 cities."
Has NovoTTF-200A been previously investigated in any other research studies?
"Currently, 206 NovoTTF-200A studies are ongoing with 23 in Phase 3. The main hub of these trials is located in Seoul Songpa; however, there are 4751 sites that have launched investigations into this treatment option."
How many individuals are receiving treatment through this trial?
"This clinical trial has reached its recruitment capacity, with the initial posting on July 26th 2017 and latest edit on October 7th 2022. Alternative studies are available for glioblastoma and NovoTTF-200A; 442 trials recruiting participants and 206 respectively."
Are there any known adverse effects associated with NovoTTF-200A?
"Our research team at Power assigned a value of 1 to the safety profile of NovoTTF-200A due to its Phase 1 status, which indicates that there is limited documentation concerning efficacy and safety."
Share this study with friends
Copy Link
Messenger